^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 1831169

    i
    Other names: BI 1831169, VSV-GP
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    9d
    A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=117, Recruiting, Boehringer Ingelheim | Trial primary completion date: Nov 2025 --> May 2027 | Trial completion date: Nov 2026 --> May 2028
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    ezabenlimab (BI 754091) • BI 1831169
    10ms
    Pre-clinical assessment of the therapeutic potential of a CD80-Fc-armed oncolytic virus (VSV-GP-CD80Fc) (ESMO 2023)
    Conclusions In conclusion, VSV-GP-CD80Fc is a highly potent and efficacious oncolytic virus. The usage of the CD80-Fc cargo further boosts the therapeutic potential of VSV-GP-based treatments in humans.
    Preclinical • Oncolytic virus • IO biomarker
    |
    CD80 (CD80 Molecule)
    |
    BI 1831169
    11ms
    Therapeutic efficacy of a VSV-GP-based human papilloma virus vaccine in a murine cancer model. (PubMed, J Mol Biol)
    Immunization with both vectors protected mice in prophylactic and in therapeutic TC-1 tumor models with HPVp1 being more effective in the prophylactic setting. Taken together, VSV-GP is a promising candidate as therapeutic HPV vaccine and first position of the vaccine antigen in a VSV-derived vector seems to be superior to fifth position.
    Preclinical • Journal • IO biomarker
    |
    BI 1831169
    almost4years
    The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer. (PubMed, Br J Cancer)
    These studies present a case for a predominantly lytic treatment effect of VSV-GP in a syngeneic mouse lung cancer model.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2)
    |
    BI 1831169